---
document_datetime: 2023-09-21 17:14:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/avaglim-epar-procedural-steps-taken-authorisation_en.pdf
document_name: avaglim-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4122671
conversion_datetime: 2025-12-19 02:04:31.716589
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  SmithKline  Beecham  plc  submitted  on  27  May  2005  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Avaglim,  through  the  centralised procedure.

•

<!-- image -->

Medicinal product no longer authorise The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application, (i.e. complete dossier with administrative, quality, non-clinical and clinical data) Scientific Advice: The applicant did not seek scientific advice at the CHMP. Licensing status: At positive opinion, Avaglim has been given a Marketing Authorisation in Canada on 21 October 2004 and the United States of America 29 th November 2005.  A new application has been filed in the following countries: Chile, Columbia, Philippines, South Africa, South Korea and Switzerland. The Rapporteur and Co-Rapporteur appointed by the CHMP were Rapporteur Dr. J.F.F. Lekkerkerker Co-Rapporteur Dr. P. Neels 2. Steps taken for the assessment of the product · The application was received by the EMEA on 27 May 2005. · The procedure started on 15 June 2005. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 26 August 2005 . The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 7 September 2005 . · During  the  meeting  on  10-13  October  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 13 October 2005). · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  13 January 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 27 February 2006 . · During the CHMP meeting on 20-23 March 2006 the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. · The applicant submitted the responses to the CHMP consolidated List of outstanding issues on 28 March 2006 · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding issues to all CHMP members on 11 April 2006. During the meeting on 24-27 April 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Avaglim  on  27  April  2006.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 24 April 2006. The European Commission granted a marketing authorisation valid throughout the European Union for Avaglim on 27 June 2006.